Eversept Partners LP Invests $12.69 Million in Bristol Myers Squibb Company $BMY

Eversept Partners LP acquired a new position in shares of Bristol Myers Squibb Company (NYSE:BMY) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 235,293 shares of the biopharmaceutical company’s stock, valued at approximately $12,692,000.

Other institutional investors have also modified their holdings of the company. Swiss RE Ltd. purchased a new stake in shares of Bristol Myers Squibb during the 4th quarter worth $25,000. Physician Wealth Advisors Inc. lifted its position in shares of Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 202 shares during the last quarter. Darwin Wealth Management LLC purchased a new stake in shares of Bristol Myers Squibb during the 2nd quarter worth $25,000. EQ Wealth Advisors LLC purchased a new stake in shares of Bristol Myers Squibb during the 4th quarter worth $32,000. Finally, Garner Asset Management Corp purchased a new stake in shares of Bristol Myers Squibb during the 4th quarter worth $35,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol Myers Squibb Trading Down 0.9%

NYSE BMY opened at $55.41 on Thursday. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. The firm has a market cap of $113.15 billion, a PE ratio of 15.56, a P/E/G ratio of 0.16 and a beta of 0.24. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $62.89. The firm’s fifty day moving average is $57.52 and its two-hundred day moving average is $57.08.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. The company had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. Bristol Myers Squibb’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period in the previous year, the business posted $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Analysts expect that Bristol Myers Squibb Company will post 6.32 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be paid a $0.63 dividend. The ex-dividend date is Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.5%. Bristol Myers Squibb’s payout ratio is currently 70.79%.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on BMY shares. Royal Bank Of Canada started coverage on shares of Bristol Myers Squibb in a research report on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 price objective for the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bristol Myers Squibb in a research report on Monday, March 23rd. Citigroup reiterated a “neutral” rating on shares of Bristol Myers Squibb in a research note on Friday, May 1st. Guggenheim reiterated a “buy” rating and set a $72.00 price target on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Finally, Bank of America cut their price target on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating on the stock in a research note on Thursday, April 9th. Eight research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $61.31.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of Bristol Myers Squibb stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the transaction, the executive vice president directly owned 159,248 shares in the company, valued at approximately $9,820,824.16. The trade was a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.05% of the company’s stock.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb announced a dividend, reinforcing its shareholder-return profile and highlighting management’s confidence in cash generation. Bristol Myers Squibb Announces Dividend
• Positive Sentiment: The company reported positive multiple myeloma data for two pipeline candidates at the EHA 2026 conference, supporting the long-term growth outlook for its hematology franchise. EHA26: BMS touts positive multiple myeloma data for two pipeline candidates
• Positive Sentiment: New real-world kidney cancer study results pointed to durable immunotherapy momentum, which could strengthen confidence in Bristol Myers Squibb’s oncology portfolio. Bristol-Myers Squibb’s Real World Kidney Cancer Study Signals Durable Immunotherapy Momentum
• Neutral Sentiment: Investor and analyst interest has picked up around BMY, but the “most searched” and “hold” ratings items appear more like sentiment checks than fresh catalysts. Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
• Neutral Sentiment: Bristol Myers Squibb also appointed a new general manager for Saudi Arabia and Gulf countries, a regional leadership change that is unlikely to move the stock on its own. Bristol Myers Squibb Appoints Mayada Al-Ahmad as General Manager for Saudi Arabia & Gulf Countries
• Negative Sentiment: Broader market coverage still points to a consensus “Hold” rating, which can temper enthusiasm even as pipeline developments remain encouraging. Bristol Myers Squibb Company (NYSE:BMY) Receives Consensus Rating of “Hold” from Analysts

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.